Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2015

Open Access 01-12-2015 | Research

Bilirubin is independently associated with oxidized LDL levels in young obese patients

Authors: Henrique Nascimento, Ana Inês Alves, Susana Coimbra, Cristina Catarino, Diana Gomes, Elsa Bronze-da-Rocha, Elísio Costa, Petronila Rocha-Pereira, Luísa Aires, Jorge Mota, Helena Ferreira Mansilha, Carla Rêgo, Alice Santos-Silva, Luís Belo

Published in: Diabetology & Metabolic Syndrome | Issue 1/2015

Login to get access

Abstract

Background

Bilirubin can prevent lipid oxidation in vitro, but the association in vivo with oxidized low-density lipoprotein (Ox-LDL) levels has been poorly explored. Our aim is to the association of Ox-LDL with total bilirubin (TB) levels and with variables related with metabolic syndrome and inflammation, in young obese individuals.

Findings

125 obese patients (13.4 years; 53.6% females) were studied. TB, lipid profile including Ox-LDL, markers of glucose metabolism, and levels of C-reactive protein (CRP) and adiponectin were determined. Anthropometric data was also collected.
In all patients, Ox-LDL correlated positively with BMI, total cholesterol, LDLc, triglycerides (TG), CRP, glucose, insulin and HOMAIR; while inversely with TB and HDLc/Total cholesterol ratio (P < 0.05 for all). In multiple linear regression analysis, LDLc, TG, HDLc and TB levels were significantly associated with Ox-LDL (standardized Beta: 0.656, 0.293, −0.283, −0.164, respectively; P < 0.01 for all). After removing TG and HDLc from the analysis, HOMAIR was included in the regression model. In this new model, LDLc remained the best predictor of Ox-LDL levels (β = 0.665, P < 0.001), followed by TB (β = −0.202, P = 0.002) and HOMAIR (β = 0.163, P = 0.010).

Conclusions

Lower bilirubin levels may contribute to increased LDL oxidation in obese children and adolescents, predisposing to increased cardiovascular risk.
Literature
1.
Wu TW, Fung KP, Wu J, Yang CC, Weisel RD: Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 1996, 51:859–862. 10.1016/0006-2952(95)02395-XCrossRefPubMed
2.
Boon AC, Hawkins CL, Bisht K, Coombes JS, Bakrania B, Wagner KH, et al.: Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome. Free Radic Biol Med 2012, 52:2120–2127. 10.1016/j.freeradbiomed.2012.03.002CrossRefPubMedCentralPubMed
3.
Stojanov M, Stefanovic A, Dzingalasevic G, Ivanisevic J, Miljkovic M, Mandic-Radic S, et al.: Total bilirubin in young men and women: association with risk markers for cardiovascular diseases. Clin Biochem 2013, 46:1516–1519. 10.1016/j.clinbiochem.2013.06.020CrossRefPubMed
4.
Horsfall LJ, Nazareth I, Petersen I: Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 2012, 126:2556–2564. 10.1161/CIRCULATIONAHA.112.114066CrossRefPubMed
5.
McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A: Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. BMC Cardiovasc Disord 2012, 12:16. 10.1186/1471-2261-12-16CrossRefPubMedCentralPubMed
6.
Lin LY, Kuo HK, Hwang JJ, Lai LP, Chiang FT, Tseng CD, et al.: Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009, 203:563–568. 10.1016/j.atherosclerosis.2008.07.021CrossRefPubMed
7.
Nascimento H, Costa E, Rocha S, Lucena C, Rocha-Pereira P, Rego C, et al.: Adiponectin and markers of metabolic syndrome in obese children and adolescents: impact of 8-mo regular physical exercise program. Pediatr Res 2014, 76:159–165. 10.1038/pr.2014.73CrossRefPubMed
8.
Norris AL, Steinberger J, Steffen LM, Metzig AM, Schwarzenberg SJ, Kelly AS: Circulating oxidized LDL and inflammation in extreme pediatric obesity. Obesity (Silver Spring) 2011, 19:1415–1419. 10.1038/oby.2011.21CrossRef
9.
Ryder JR, Vega-Lopez S, Djedjos CS, Shaibi GQ: Abdominal adiposity, insulin resistance, and oxidized low-density lipoproteins in Latino adolescents. Diabetol Metab Syndr 2013, 5:72. 10.1186/1758-5996-5-72CrossRefPubMedCentralPubMed
10.
National Center for Health Statistics Centers for Disease Control and Prevention Hyattsville M: ANALYTIC AND REPORTING GUIDELINES: The Third National Health and Nutrition Examination Survey, NHANES III (1988–94). Book ANALYTIC AND REPORTING GUIDELINES: The Third National Health and Nutrition Examination Survey, NHANES III (1988–94) 1996.
11.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412–419. 10.1007/BF00280883CrossRefPubMed
12.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499–502.PubMed
13.
Chait A, Brazg RL, Tribble DL, Krauss RM: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993, 94:350–356. 10.1016/0002-9343(93)90144-ECrossRefPubMed
14.
de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991, 11:298–306. 10.1161/01.ATV.11.2.298CrossRefPubMed
15.
Kontush A: HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc Res 2014, 103:341–349. 10.1093/cvr/cvu147CrossRefPubMed
16.
Mertens A, Holvoet P: Oxidized LDL and HDL: antagonists in atherothrombosis. Faseb J 2001, 15:2073–2084. 10.1096/fj.01-0273revCrossRefPubMed
17.
do Sameiro-Faria M, Kohlova M, Ribeiro S, Rocha-Pereira P, Teixeira L, Nascimento H, et al.: Potential cardiovascular risk protection of bilirubin in end-stage renal disease patients under hemodialysis. Biomed Res Int 2014, 2014:175286.PubMedCentralPubMed
18.
Kelly AS, Jacobs DR Jr, Sinaiko AR, Moran A, Steffen LM, Steinberger J: Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatr Diabetes 2010, 11:552–555. 10.1111/j.1399-5448.2009.00640.xCrossRefPubMedCentralPubMed
19.
Belo L, Nascimento H, Kohlova M, Bronze-da-Rocha E, Fernandes J, Costa E, et al.: Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymorphism in young obese. PLoS One 2014, 9:e98467. 10.1371/journal.pone.0098467CrossRefPubMedCentralPubMed
20.
Nascimento H, Silva L, Lourenco P, Weinfurterova R, Castro E, Rego C, et al.: Lipid profile in Portuguese obese children and adolescents: interaction of apolipoprotein E polymorphism with adiponectin levels. Arch Pediatr Adolesc Med 2009, 163:1030–1036.PubMed
Metadata
Title
Bilirubin is independently associated with oxidized LDL levels in young obese patients
Authors
Henrique Nascimento
Ana Inês Alves
Susana Coimbra
Cristina Catarino
Diana Gomes
Elsa Bronze-da-Rocha
Elísio Costa
Petronila Rocha-Pereira
Luísa Aires
Jorge Mota
Helena Ferreira Mansilha
Carla Rêgo
Alice Santos-Silva
Luís Belo
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2015
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-7-4

Other articles of this Issue 1/2015

Diabetology & Metabolic Syndrome 1/2015 Go to the issue

Short report

A new compound heterozygosis for inactivating mutations in the glucokinase gene as cause of permanent neonatal diabetes mellitus (PNDM) in double-first cousins

Research

High glucose induces and activates Toll-like receptor 4 in endothelial cells of diabetic retinopathy

Short report

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Research

Differential expression of genes encoding proteins of the HGF/MET system in insulinomas

Research

Diagnostic performance analysis for diabetic cardiovascular autonomic neuropathy based on short-term heart rate variability using Bayesian methods: preliminary analysis

Review

Regulation of hepatic TRB3/Akt interaction induced by physical exercise and its effect on the hepatic glucose production in an insulin resistance state
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits